Eli Lilly is handing China sales rights for a breast cancer drug to Innovent Biologics

Eli Lilly has transferred sales rights for the breast cancer drug Verzenios in mainland China to Innovent Biologics. Innovent will manage importing, marketing, and distribution as generic competition emerges.